Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Privilège Ventures is a Swiss, FINMA-authorized venture capital firm based in Lugano, founded in 2021. The firm focuses on early-stage investments, particularly in HealthTech, CleanTech, and AgriFoodTech. Their team combines extensive experience in entrepreneurship, management, finance, and governance.
Privilège Ventures invests in early-stage companies, specifically targeting gender-mixed startups from pre-seed to Series A stages. Their investment strategy emphasizes long-term value creation and strategic partnerships, primarily within Europe and with a strong focus on Switzerland.
Notable portfolio companies include AVELO AG, which is developing a novel breath aerosol collection kit for airborne Mycobacterium tuberculosis; ANNAIDA, an EIC Transition beneficiary that recently closed pre-Series A funding; and SMEETZ, which is enhancing its operations through strategic partnerships in Switzerland.
Submit your pitch through their form at privilege-ventures.com or email info@privilege-ventures.com with your deck.
Yes, Privilège Ventures often leads investment rounds, particularly in their focus sectors of HealthTech, CleanTech, and AgriFoodTech.
The firm is open to follow-on investments, especially for startups that align with their focus on gender diversity and long-term value creation.
Specific details about the fund size are not publicly disclosed, but the firm is actively building its portfolio in early-stage investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.